Meeting
2022 ASCO Annual Meeting
EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i).
Authors
Michelino De Laurentiis
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"-Breast Oncology Unit, Naples, Italy
Michelino De Laurentiis , Luis Costa , Joseph Gligorov , Ann Knop , Elzbieta Senkus-Konefka , José A. García-Sáenz , Peter Schmid , Aurelia Heniquez , Paolo Serra , Albert Reising , Sherko Kuemmel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
HER2-Positive
Clinical Trial Registration Number
NCT05038735; EUDRACT2021-001966-39
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS1109)
DOI
10.1200/JCO.2022.40.16_suppl.TPS1109
Abstract #
TPS1109
Poster Bd #
485a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
First Author: Hope S. Rugo
Poster
2023 ASCO Annual Meeting
A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).
First Author: Sara A. Hurvitz
Poster
2023 ASCO Annual Meeting
Alpelisib + endocrine therapy in patients with PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, advanced breast cancer: Analysis of all 3 cohorts of the BYLieve study.
First Author: Stephen Chia
Poster
2019 ASCO Annual Meeting
Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial.
First Author: Dejan Juric